Literature DB >> 30593687

Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.

L S Spekhorst1, J M P A van den Reek2, A C Knulst1, H Röckmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30593687     DOI： 10.1111/all.13714

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  2 in total

1.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

Review 2.  EUFOREA consensus on biologics for CRSwNP with or without asthma.

Authors:  Wytske J Fokkens; Valerie Lund; Claus Bachert; Joaquim Mullol; Leif Bjermer; Jean Bousquet; Giorgio W Canonica; Lauren Deneyer; Martin Desrosiers; Zuzana Diamant; Joseph Han; Enrico Heffler; Claire Hopkins; Roger Jankowski; Guy Joos; Andrew Knill; Jivianne Lee; Stella E Lee; Gert Mariën; Benoit Pugin; Brent Senior; Sven F Seys; Peter W Hellings
Journal:  Allergy       Date:  2019-07-15       Impact factor: 13.146
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.